This deal removes geographic fragmentation and unlocks full global optionality for felzartamab, which is in late-stage trials for multiple high-unmet-need immune diseases. Given China's large patient pool for IgAN and PMN, the market opportunity is substantial. Monitor upcoming Phase 3 readouts as key catalysts for valuation expansion.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $183.33entry
- T+1 · 7mo ago +1.01%α +1.66% · $185.18
- T+5 · 7mo ago −1.51%α −2.42% · $180.56
- T+20 · 6mo ago +4.31%α +0.11% · $191.23
- T+60 · 4mo ago +4.70%α −1.38% · $191.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Biogen has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma, consolidating full global rights to the CD38-directed antibody. The deal includes a $100 million upfront payment and up to $750 million in potential milestone payments, plus tiered royalties on future sales in China.
Key Financial Metrics
Key Facts
- Biogen acquires exclusive Greater China rights to felzartamab from TJ Biopharma
- Total potential deal value: up to $850 million ($100M upfront, $750M in milestones)
- Biogen now holds full worldwide rights to felzartamab, a potential pipeline-in-a-product for immune-mediated diseases
- Felzartamab is in global Phase 3 trials for IgA nephropathy (IgAN), primary membranous nephropathy (PMN), and kidney transplant rejection
- China has one of the largest patient populations globally for IgAN and PMN, representing a major commercial opportunity
- Biogen will lead development, manufacturing, and commercialization in China; TJ Bio to manufacture for multiple myeloma indication
Financial Impact
$100 million upfront expense in Q2 2026; potential additional $750 million in milestone payments tied to commercial success
Risk Factors
- Felzartamab remains investigational with no regulatory approvals yet; clinical trial results may not meet endpoints
- Milestone payments are contingent on commercial success, which depends on regulatory approval and market adoption
- Increased R&D expense from upfront $100M charge may pressure near-term earnings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276893 |
Track record
34 reports on BIIB
9 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers